At Aurigene, we have the world-class infrastructure to provide end-to-end services (from discovery through commercialization) to our clients. We operate state-of-the-art R and D and manufacturing facilities that are audited by major international regulatory agencies. The R and D facilities are in Hyderabad and Bangalore with a total built area of over 300,000 Sq.m. This facility is equipped with multiple fume hoods and special-purpose labs such as:
Peptide laboratory Oligonucleotide laboratory High potent laboratory Kilo labs for scale-up
The R and D facilities also house state-of-the-art analytical infrastructure and safety study labs. We have access to 8 cGMP API manufacturing sites with over thousands of kilo liter capacity. Our manufacturing facilities can handle a variety of unit operations and multiple technologies such as steroids, peptides, high potent APIs, carbohydrates and mPEGs.
We operate our facilities by international sustainability frameworks and our efforts in sustainability are recognized by DJSI (Dow Jones Sustainability Indices), FTSE4Good Index, CDP (Carbon Disclosure Project), S&P BSE Carbonex, S&P BSE Greenex, Bloomberg Gender-Equality IndexSpeak to our experts
JUNE 28, 2022
Neoantigen specific T cells for cellular cancer immunotherapy An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence...Read More
JANUARY 04, 2021
Building successful long-term partnerships with CDMOs from early drug discovery through commercialization Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contr...Read More
We are always looking for ways to enhance the sustainability of our products and services. Our team successfully developed a scalable manufacturing process for the API product of one of our Biotech clients using eco-friendly manufacturing technologies. Read the case study to learn more. ...Read More
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...Read More
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...Read More
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...Read More
An efficient approach for the synthesis of various imidazoquinoxalines and spiroquinoxalinones has been reported from 2-(1H-imidazol-1-yl) aniline and .. ...Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.